This dataset investigates the effectiveness of p53 reactivation in treating glioblastoma. They achieve this by treating multiple patients with differing levels of MDM2 inhibitor navtemadlin. Tumor tissue samples were sequenced, and it was shown that that clinically achievable doses of navtemadlin exert pharmacodynamic effects and suggest that combined treatment with standard-of-care DNA damaging chemotherapy may be a route to more durable survival benefits. (Publication)

Check it out on the CCKP